INSMED (INSM) debt: $547M
INSMED had $547M of long-term debt on Dec 31, 2025, including the part due within a year, down 51.3% from $1.1B a year earlier.
From INSMED's filings with the SEC · Read the filing · INSM stock page
INSMED debt by year
#1,091 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $547M | -51% |
| Dec 31, 2024 | $1.1B | -5% |
| Dec 31, 2023 | $1.2B | +2% |
| Dec 31, 2022 | $1.2B | +44% |
| Dec 31, 2021 | $800M | – |
Debt of similar companies
Companies in the same industry as INSMED, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| BeOne Medicines | $836M | Dec 31, 2025 |
| Sarepta Therapeutics | $829M | Dec 31, 2025 |
| Phibro Animal Health | $624M | Dec 31, 2025 |
| Amphastar Pharmaceuticals | $620M | Dec 31, 2025 |
| Biomarin Pharmaceutical | $597M | Dec 31, 2025 |
| INSMED | $547M | Dec 31, 2025 |
| Pacira BioSciences | $372M | Dec 31, 2025 |
Questions and answers
What is INSMED's debt?
INSMED had $547M of long-term debt on Dec 31, 2025, including the part due within a year, down 51.3% from $1.1B a year earlier.
Numbers as reported in INSMED's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology